Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland

被引：0
|
作者：
Pardo, E. [1 ]
Barbier, M. [2 ]
Panje, C. [3 ]
Gautschi, O. [4 ]
Lupatsch, J. [5 ]
机构：
[1] Canton Hosp Lucerne, Med Oncol, Internal Med, Luzern, Switzerland
[2] Univ Basel, Inst Pharmaceut Med Ecpm, Basel, Switzerland
[3] Cantonal Hosp St Gallen, Radiat Oncol, St Gallen, Switzerland
[4] Canton Hosp Lucerne, Luzern, Switzerland
[5] Univ Basel, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
cost-effectiveness; Pembrolizumab; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.03
引用
收藏
页码：S992 / S992
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
    Liu, Qiao
    Zhou, Zhen
    Luo, Xia
    Yi, Lidan
    Peng, Liubao
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [2] A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
    Michaela Carla Barbier
    Esther Pardo
    Cédric Michael Panje
    Oliver Gautschi
    Judith Eva Lupatsch
    The European Journal of Health Economics, 2021, 22 : 669 - 677
  • [3] A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
    Barbier, Michaela Carla
    Pardo, Esther
    Panje, Cedric Michael
    Gautschi, Oliver
    Lupatsch, Judith Eva
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (05): : 669 - 677
  • [4] Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
    Insinga, Ralph P.
    Vanness, David J.
    Feliciano, Josephine L.
    Vandormael, Kristel
    Traore, Sory
    Burke, Thomas
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1191 - 1205
  • [5] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [6] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [7] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Rihua Cheng
    Zhen Zhou
    Qiao Liu
    Advances in Therapy, 2023, 40 : 4298 - 4309
  • [8] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Cheng, Rihua
    Zhou, Zhen
    Liu, Qiao
    ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
  • [9] Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (> 50%) metastatic squamous and non-squamous non-small cell lung cancer in France
    Chouaid, Christos
    Bensimon, Lionel
    Clay, Emilie
    Millier, Aurelie
    Levy-Bachelot, Laurie
    Huang, Min
    Levy, Pierre
    LUNG CANCER, 2019, 127 : 44 - 52
  • [10] Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Aebi, Stefan
    Dedes, Konstantin
    Diebold, Joachim
    Pietrini, Mario
    Klingbiel, Dirk
    Von Moos, Roger
    Gautschi, Oliver
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1430 - S1431
12345